Quest Diagnostics (DGX) official guidance

| Capital expenditures | Approximately $550 million | | Approximately $550 million | |

Cash from operations to be approximately $1.8 billion, and capital expenditures to be approximately $550 million.

| Capital expenditures | Approximately $550 million | | Approximately $550 million | |

Cash from operations to be approximately $1.75 billion, capital expenditures to be approximately $550 million, share count and interest expense to be consistent with 2025, and our 2026 guidance reflects the following considerations.

| Capital expenditures | Approximately $550 million | | Approximately $550 million | |

Capital expenditures are expected to be approximately $550 million.

| Capital expenditures | Approximately $550 million | |

We remain on track to deliver 3% in annual cost savings and productivity improvements through our Invigorate program.

Through our Invigorate program, we expect to continue to deliver 3% in annual cost savings and productivity improvements.

Share count is expected to be slightly below 2025.

Cash from operations to be approximately $1.75 billion, capital expenditures to be approximately $550 million, share count and interest expense to be consistent with 2025, and our 2026 guidance reflects the following considerations.

Our share count and interest expense are expected to be consistent with 2025.

Adjusted effective tax rate is now expected to be consistent with 2025.

Based on the favorable resolution of various tax contingencies in the second quarter, the full year adjusted effective tax rate is expected to be consistent with 2025.

•Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35

Reported EPS to be in a range of $9.97-$10.17, and adjusted EPS in a range of $11.05-$11.25.

•Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25

Reported EPS to be in a range of $9.58-$9.78, and adjusted EPS in a range of $10.63-$10.83.

| Adjusted diluted EPS | $10.63 | $10.83 | $10.50 | $10.70 |

Reported EPS is expected to be in a range of $9.45-$9.65, and adjusted EPS in a range of $10.50-$10.70.

| Adjusted diluted EPS | $10.50 | $10.70 |

| Cash provided by operations | Approximately $1.90 billion | | Approximately $1.80 billion | |

Cash from operations to be approximately $1.8 billion, and capital expenditures to be approximately $550 million.

| Cash provided by operations | Approximately $1.80 billion | | Approximately $1.75 billion | |

Cash from operations to be approximately $1.75 billion, capital expenditures to be approximately $550 million, share count and interest expense to be consistent with 2025, and our 2026 guidance reflects the following considerations.

| Cash provided by operations | Approximately $1.75 billion | | Approximately $1.75 billion | |

Cash from operations is expected to be approximately $1.75 billion.

| Cash provided by operations | Approximately $1.75 billion | |

Operating margin is expected to expand versus the prior year.

Operating margin is expected to expand versus the prior year.

Operating margin is expected to expand versus the prior year.

Nova expenses are unchanged for the full year, but we anticipate increased spend in the H2 of the year compared to prior expectations.

| Net revenues | $12.065 billion | $12.105 billion | $11.95 billion | $12.05 billion |

We now expect revenues to be between $11.95 billion and $12.05 billion, reflecting a growth rate of 8.3%-9.2%.

•Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion

We now expect revenues to be between $11.78 billion and $11.9 billion, a growth rate of 6.8%-7.8%.

| Net revenues | $11.78 billion | $11.90 billion | $11.70 billion | $11.82 billion |

Turning now to our full-year 2026 guidance. Revenues are expected to be between $11.7 billion-$11.82 billion, which represents a growth rate of 6%-7.1%.

| Net revenues | $11.70 billion | $11.82 billion |

Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

Represents estimated pre-tax amortization expenses of $149 million.

Represents estimated pre-tax amortization expenses of $155 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

Reported EPS to be in a range of $9.97-$10.17, and adjusted EPS in a range of $11.05-$11.25.

•Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25

| Reported diluted EPS | $9.58 | $9.78 | $9.45 | $9.65 |

Reported EPS is expected to be in a range of $9.45-$9.65, and adjusted EPS in a range of $10.50-$10.70.

| Reported diluted EPS | $9.45 | $9.65 |

Principally represents estimated pre-tax net losses of $9 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions.

Principally represents estimated pre-tax net losses of $10 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions.

Principally includes estimated pre-tax net charges of $12 million associated with the estimated change in the fair value of the contingent consideration accrual associated with previous acquisitions.

Represents estimated pre-tax charges of $21 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.

Represents estimated pre-tax charges of $16 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.

Represents estimated pre-tax charges of $12 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.

Cash from operations to be approximately $1.75 billion, capital expenditures to be approximately $550 million, share count and interest expense to be consistent with 2025, and our 2026 guidance reflects the following considerations.

Our share count and interest expense are expected to be consistent with 2025.